Family history of cancer and the risk of childhood brain tumors: a pooled analysis of the ESCALE and ESTELLE studies (SFCE).


Journal

Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 17 01 2019
accepted: 05 08 2019
pubmed: 11 8 2019
medline: 12 11 2019
entrez: 11 8 2019
Statut: ppublish

Résumé

Although some specific genetic syndromes such as neurofibromatosis (NF) have been identified as risk factor of childhood brain tumors (CBT), the potential role of inherited susceptibility in CBT has yet to be elucidated. To further investigate this, we conducted a pooled analysis of two nationwide case-control studies ESCALE and ESTELLE. The mothers of 509 CBT cases and 3,102 controls aged under 15 years who resided in France at diagnosis/interview, frequency-matched by age and gender, responded to a telephone interview conducted by trained interviewers. Pooled odds ratio (OR) and 95% confidence intervals (95% CI) were estimated using unconditional logistic regression. CBT was significantly associated with the family history of cancer in relatives (OR 1.2, 95% CI 1.0-1.5). The OR was slightly higher for maternal relatives than for paternal relatives, and when at least two relatives had a history of cancer. CBT was significantly associated with a family history of brain tumor (OR 2.1, 95% CI 1.3-3.7). This association seemed stronger for first-degree relatives (mother, father, and siblings), for whom, by contrast, no association was seen for cancers other than CBT. No specificity by CBT subtypes or by age of the children were found for any of these findings. Our findings support the hypothesis of a familial susceptibility of CBT, not due to being a known NF carrier.

Identifiants

pubmed: 31399828
doi: 10.1007/s10552-019-01214-x
pii: 10.1007/s10552-019-01214-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1075-1085

Auteurs

Nicolas Vidart d'Egurbide Bagazgoïtia (N)

CRESS, UMR1153, Inserm, Paris Descartes University, Paris, France. nicolas.vidart@inserm.fr.

Helen D Bailey (HD)

CRESS, UMR1153, Inserm, Paris Descartes University, Paris, France.
Telethon Kids Institute, The University of Western Australia, Perth, WA, Australia.

Laurent Orsi (L)

CRESS, UMR1153, Inserm, Paris Descartes University, Paris, France.

Léa Guerrini-Rousseau (L)

Gustave Roussy, Département de cancérologie de l'enfant et de L'adolescent, Villejuif, France.

Anne-Isabelle Bertozzi (AI)

Unité d'Hémato-Immuno-Oncologie pédiatrique, Pôle Pédiatrique, CHU Toulouse, Toulouse, France.

Cécile Faure-Conter (C)

Institut d'hématologie et d'oncologie pédiatrique, IHOPe, Centre Léon Bérard, Lyon, France.

Pierre Leblond (P)

Pediatric Oncology Unit, Oscar Lambret Comprehensive Cancer Center, Lille, France.

Isabelle Pellier (I)

Unité immuno-hémato-oncopédiatrie, CHU d'Angers, Angers, France.

Claire Freycon (C)

Clinique de pédiatrie, Hôpital Couple Enfant, CHU Grenoble-Alpes, Grenoble, France.

François Doz (F)

Département de Pédiatrie -Adolescents Et Jeunes Adultes, Institut Curie, Et Université Paris Descartes, Paris, France.

Stéphanie Puget (S)

Service de Neurochirurgie pédiatrique, Hôpital Necker-Enfants Malades, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Stéphane Ducassou (S)

Service d'onco-hématologie pédiatrique, Hôpital Pellegrin Tripode, Bordeaux, France.

Brigitte Lacour (B)

CRESS, UMR1153, Inserm, Paris Descartes University, Paris, France.
RNCE - National Registry of Childhood Cancers, Inserm, Villejuif and CHU de Nancy, France.

Jacqueline Clavel (J)

CRESS, UMR1153, Inserm, Paris Descartes University, Paris, France.
RNCE - National Registry of Childhood Cancers, Inserm, Villejuif and CHU de Nancy, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH